van Moorselaar RJA - Search Results

1

Prostate Specific Membrane Antigen Positron Emission Tomography/Computerized Tomography in the Evaluation of Initial Response in Candidates Who Underwent Salvage Radiation Therapy after Radical Prostatectomy for Prostate Cancer.

Meijer D, Luiting HB, van Leeuwen PJ, Remmers S, Jansen BHE, Bodar YJL, Witteveen T, Schaake EE, van der Poel HG, Wondergem M, Busstra MB, Nieuwenhuijzen JA, Meijnen P, Brabander T, van Moorselaar RJA, Hendrikse NH, Oprea-Lager DE, Roobol MJ, Vis AN. Meijer D, et al. Among authors: van leeuwen pj, van moorselaar rja, van der poel hg. J Urol. 2021 Apr;205(4):1100-1109. doi: 10.1097/JU.0000000000001437. Epub 2020 Nov 18. J Urol. 2021. PMID: 33207138

2

Antitumoral effects of liarozole in androgen-dependent and independent R3327-Dunning prostate adenocarcinomas.

Dijkman GA, Van Moorselaar RJ, Van Ginckel R, Van Stratum P, Wouters L, Debruyne FM, Schalken JA, de Coster R. Dijkman GA, et al. J Urol. 1994 Jan;151(1):217-22. doi: 10.1016/s0022-5347(17)34920-0. J Urol. 1994. PMID: 8254818

3

Prostate perfusion in patients with locally advanced prostate carcinoma treated with different hyperthermia techniques.

van Vulpen M, Raaymakers BW, de Leeuw AA, van de Kamer JB, van Moorselaar RJ, Hobbelink MG, Battermann JJ, Lagendijk JJ. van Vulpen M, et al. J Urol. 2002 Oct;168(4 Pt 1):1597-602. doi: 10.1016/S0022-5347(05)64527-2. J Urol. 2002. PMID: 12352464

4

External beam radiation therapy followed by interstitial radiotherapy with iridium-192 for solitary bladder tumours: results of 111 treated patients.

van Onna IE, Oddens JR, Kok ET, van Moorselaar RJ, Bosch JL, Battermann JJ. van Onna IE, et al. Eur Urol. 2009 Jul;56(1):113-21. doi: 10.1016/j.eururo.2008.07.043. Epub 2008 Aug 21. Eur Urol. 2009. PMID: 18722048

5

Intraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancer.

van der Sluis TM, Vis AN, van Moorselaar RJ, Bui HN, Blankenstein MA, Meuleman EJ, Heijboer AC. van der Sluis TM, et al. BJU Int. 2012 Jan;109(2):176-82. doi: 10.1111/j.1464-410X.2011.10651.x. Epub 2011 Oct 12. BJU Int. 2012. PMID: 21992222 Review.

6

Intraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.

van der Sluis TM, Meuleman EJ, van Moorselaar RJ, Bui HN, Blankenstein MA, Heijboer AC, Vis AN. van der Sluis TM, et al. BJU Int. 2012 Jan;109(2):183-8. doi: 10.1111/j.1464-410X.2011.10652.x. Epub 2011 Oct 12. BJU Int. 2012. PMID: 21992404 Review.

7

Lower testosterone levels with luteinizing hormone-releasing hormone agonist therapy than with surgical castration: new insights attained by mass spectrometry.

van der Sluis TM, Bui HN, Meuleman EJ, Heijboer AC, Hartman JF, van Adrichem N, Boevé E, de Ronde W, van Moorselaar RJ, Vis AN. van der Sluis TM, et al. J Urol. 2012 May;187(5):1601-6. doi: 10.1016/j.juro.2011.12.063. Epub 2012 Mar 14. J Urol. 2012. PMID: 22425112

8

Serum testosterone plays an important role in the metastatic ability of castration resistant prostate cancer.

van der Sluis TM, Bijnsdorp IV, Jacobs JJ, Meuleman EJ, Rozendaal L, Geldof AA, van Moorselaar RJ, Vis AN. van der Sluis TM, et al. World J Urol. 2013 Apr;31(2):261-6. doi: 10.1007/s00345-012-0972-4. Epub 2012 Oct 19. World J Urol. 2013. PMID: 23080125

9

Relationship between body mass index and serum testosterone concentration in patients receiving luteinizing hormone-releasing hormone agonist therapy for prostate cancer.

van der Sluis TM, van Moorselaar RJ, Meuleman EJ, ter Haar RW, Bui HN, Heijboer AC, Vis AN. van der Sluis TM, et al. Urology. 2013 May;81(5):1005-9. doi: 10.1016/j.urology.2013.01.014. Epub 2013 Mar 7. Urology. 2013. PMID: 23465153

10

Risk of disease flare with LHRH agonist therapy in men with prostate cancer: myth or fact?

Vis AN, van der Sluis TM, Al-Itejawi HHM, van Moorselaar RJA, Meuleman EJH. Vis AN, et al. Among authors: van der sluis tm, van moorselaar rja. Urol Oncol. 2015 Jan;33(1):7-15. doi: 10.1016/j.urolonc.2014.04.016. Epub 2014 Aug 20. Urol Oncol. 2015. PMID: 25159013 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

182 results

Search Page